Therapeutic Kinase Inhibitors

·
· Current Topics in Microbiology and Immunology 第 355 本图书 · Springer Science & Business Media
5.0
1 条评价
电子书
234
评分和评价未经验证  了解详情

关于此电子书

Cancer drug development is currently undergoing a profound shift. Drugs targeting fundamental cellular processes such DNA-replication and microtubule function, often referred to as “chemotherapy” and still the backbone of most cancer treatment regimens, are increasingly being complemented by or replaced with kinase inhibitors. This new class of drugs targets enzymes which provide growth and survival signals to cancer cells by transferring phosphate groups from Adenosine-5'-triphosphate (ATP) to other proteins, lipids, nucleotides, and carbohydrates.

This book summarizes the current state of kinase inhibitor therapy for cancer. Successful drug development relies on the expertise and dedication of many experts. To reflect this team approach to finding new kinase inhibitors and defining their optimal use for cancer treatment, the editors invited experts in academia and pharmaceutical industry to share their insights into various aspects of this process, ranging from the first chemical screens, to preclinical testing and disease-focused clinical drug development. The editors and authors hope these lessons will be instructive for the novice as well as the expert.

评分和评价

5.0
1 条评价

为此电子书评分

欢迎向我们提供反馈意见。

如何阅读

智能手机和平板电脑
只要安装 AndroidiPad/iPhone 版的 Google Play 图书应用,不仅应用内容会自动与您的账号同步,还能让您随时随地在线或离线阅览图书。
笔记本电脑和台式机
您可以使用计算机的网络浏览器聆听您在 Google Play 购买的有声读物。
电子阅读器和其他设备
如果要在 Kobo 电子阅读器等电子墨水屏设备上阅读,您需要下载一个文件,并将其传输到相应设备上。若要将文件传输到受支持的电子阅读器上,请按帮助中心内的详细说明操作。